Page 2 - Multiple Sclerosis Progression News Today

The first randomized trial to examine if older adults with multiple sclerosis can discontinue disease-modifying therapy after years of being relapse-free failed to deliver a definitive conclusion.

In a recent study of patients with early relapsing-remitting MS or clinically isolated syndrome, almost two thirds of confirmed disability accumulation occurred independently of relapses.

Autologous hematopoietic stem cell transplantation for the treatment of active secondary progressive MS is associated with better disability outcomes than other immunotherapies, a new Italian study suggests.

Updated European guidelines also include a recommendation for siponimod in progressive MS and more detailed information on drug use in pregnancy.

Different prognostic variables come together into a single predictive score.

Rituximab reduced relapses and MRI activity more effectively than dimethyl fumarate, natalizumab, and injectable therapies in a recent study. Disability did not differ between treatments, however.

Twenty-five year data show a positive shift towards earlier diagnosis and treatment of multiple sclerosis and improved prognosis over time.